AstraZeneca announced July 23 that Etcamah (camizestrant), in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor, has been approved in the European Union for the first-line treatment of advanced estrogen receptor (ER)-positive breast cancer.
According to AstraZeneca, "Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1st-line endocrine therapy in combination with a CDK4/6 inhibitor."
The approval applies to adult patients whose breast cancer is locally advanced or metastatic, is ER-positive and HER2-negative, and who have an ESR1 mutation. These patients must not have experienced disease progression during first-line endocrine therapy with a CDK4/6 inhibitor.
The combination therapy includes camizestrant and one of three CDK4/6 inhibitors: palbociclib, ribociclib, or abemaciclib. The decision follows a review of clinical data supporting the efficacy and safety of the combination in this patient population.
AstraZeneca has provided additional information and resources about the approval and treatment on its website. The company is a global biopharmaceutical business focused on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal and metabolism, and respiratory and immunology, according to AstraZeneca.
Alerts Sign-up